West Pharmaceutical Services EBIT

West Pharmaceutical Services (WST) currently reports a EBIT of $680M as of June 2026. That compares with $590M in the prior-year period — up 15.4% year over year. That is below the Healthcare sector average of $23B. Use the charts on this page to explore West Pharmaceutical Services's EBIT history and peer comparisons.

West Pharmaceutical Services's EBIT increased from $590M to $680M — a 15.4% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

West Pharmaceutical Services's EBIT of $680M is lower than the Healthcare sector average of $23B. That is roughly 97.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

West Pharmaceutical Services reported $680M in EBIT as of June 2026. That compares with $590M in the prior-year period — up 15.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $680M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $23B. From there, open related valuation or income-statement pages for West Pharmaceutical Services, and consider following WST for alerts when major investors trade the stock.